Atopic dermatitis: Therapeutic concepts evolving from new pathophysiologic insights

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:122

Review

Jung, Thomas¹  Stingl, Georg^2,3 

[1] Novartis Pharma Dev Immunol & Infect Dis Franchis, CH-4056 Basel, Switzerland

[2] Med Univ Vienna, Dept Dermatol, Div Immunol, Vienna, Austria

[3] Med Univ Vienna, Dept Dermatol, Div Allergy & Infect Dis, Vienna, Austria

关键词: Atopic dermatitis;    skin barrier function;    innate immune system;    adaptive immune system;    filaggrin;    T(H)2 cells;    T(H)17 cells;    immunotherapy;    proof-of-concept trial;   

DOI  :  10.1016/j.jaci.2008.09.042

来源: Elsevier

【 摘 要 】

Recent insights into the relevance of the epidermal barrier function and its interaction with components of the innate and adaptive immune responses in patients with atopic dermatitis (AD) give rise to a number of novel potential treatment options. In particular, the identification of loss-of-function mutations in the barrier protein filaggrin and of a diminished expression of certain antimicrobial peptides in AD skin stimulates new concepts to think beyond the T(H)1/T(H)2 paradigm. This review will focus on these most recent discoveries and will discuss new and corresponding proof-of-concept trials in patients with AD. It will further speculate on novel ways to restore the homeostasis among the 3 major components in AD skin suspected to be clinically relevant. (J Allergy Clin Immunol 2008;122:1074-81.)

【 授权许可】

Free